|
|
| | WVE-120101 Basic information |
| Product Name: | WVE-120101 | | Synonyms: | WVE-120101;Rovanersen（WVE-120101）;Rovanersen(Synonyms:WVE-120101);Rovanersen | | CAS: | 2072901-32-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | APIs | | Mol File: | Mol File | ![WVE-120101 Structure]() |
| | WVE-120101 Chemical Properties |
| form | Solid | | color | White to off-white | | Sequence | DNA,d(rGm-[P(S)]-sp-rGm-rCm-rAm-rCm-[P(S)]-sp-A-[P(S)]-sp-A-[P(S)]-sp-G-[P(S)]-sp-G-[P(S)]-sp-G-[P(S)]-sp-C-[P(S)]-sp-A-[P(S)]-sp-C-[P(R)]-sp-A-[P(S)]-sp-G-[P(S)]-sp-rAm-rCm-rUm-rUm-[P(S)]-sp-rCm) |
| | WVE-120101 Usage And Synthesis |
| Uses | Rovanersen (WVE-120101) is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen can be used for huntington’s disease research[1]. | | in vivo | In non-human primates (NHPs), Rovanersen (WVE-120101) is found in nuclear and perinuclear compartments of neurons in brain areas believed to be involved in HD pathology[1]. | | References | [1] M Meena, et al. Selectivity and Biodistribution of WVE-120101, a Potential Antisense Oligonucleotide Therapy for the Treatment of Huntington’s Disease (S56.001). AAN Enterprises. April 18, 2017; 88 (16 Supplement). |
| | WVE-120101 Preparation Products And Raw materials |
|